Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026

Core Insights - Verastem Oncology announced that multiple abstracts, including late-breaking ones, have been accepted for presentation at the AACR Annual Meeting 2026, highlighting the potential of their investigational asset VS-7375 in treating KRAS G12D-driven cancers [1][2] Group 1: Research Findings - Preclinical research demonstrated that VS-7375, a dual ON/OFF inhibitor, showed stronger and more durable tumor regressions in KRAS G12D pancreatic cancer models compared to ON-only G12D or pan-RAS inhibitors [1][4] - In the KP4 KRAS G12D pancreatic cancer model, VS-7375 maintained sustained tumor regression (mean tumor volume ~80 mm by day 30), while other inhibitors lost anti-tumor activity, showing mean tumor volume >850 mm by day 30 [4] Group 2: Presentation Details - Late-breaking abstracts will be presented on April 20, 2026, including findings on the efficacy of VS-7375 in combination with PRMT5 inhibition in pancreatic cancer [3] - Regular abstracts will be available on April 22, 2026, showcasing VS-7375's potent anti-tumor activity as a single agent and in combination with other agents [3] Group 3: Clinical Development - VS-7375 is currently in Phase 1/2 clinical trials, initiated in June 2025, evaluating its safety and efficacy in patients with advanced KRAS G12D mutant solid tumors [7] - The FDA granted Fast Track Designation to VS-7375 for first-line treatment of KRAS G12D-mutated locally advanced or metastatic pancreatic adenocarcinoma [7] Group 4: Collaboration and Strategy - Verastem's collaboration with GenFleet Therapeutics aims to advance three oncology discovery programs related to RAS/MAPK pathway-driven cancers, with VS-7375 being the lead program [8]